Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VTX-003 (Valerio Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Valerio Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
VTX-003 is a preclinical-stage precision RNA therapeutic being developed by Valerio Therapeutics (formerly Valerio Toyos). It utilizes a proprietary V-Body-oligonucleotide conjugate platform to deliver small interfering RNA (siRNA) specifically to T cells. The drug is designed to modulate exhausted T cells, particularly precursor exhausted T (Tpex) cells, to reactivate their anti-tumor activity in oncology settings. By delivering siRNA to these specific cell populations, VTX-003 aims to overcome T-cell exhaustion, a common mechanism of resistance in cancer immunotherapy.
Beyond the preview
Go deeper on VTX-003 (Valerio Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VTX-003 (Valerio Therapeutics).